BSE: 540025 | NSE: ADVENZYMES | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Advanced Enzyme Technologies Ltd is a good quality company.
The key valuation ratios of Advanced Enzyme Technologies Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Advanced Enzyme Technologies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 13.8% | 14.3% | 18.1% | 15.1% | 14.9% | 21.5% | 24.2% | 15.8% | 14.8% | 24.3% | - |
| Value Creation Index ⓘ | 0.0 | 0.0 | 0.3 | 0.1 | 0.1 | 0.5 | 0.7 | 0.1 | 0.1 | 0.7 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 126 | 139 | 173 | 212 | 222 | 247 | 283 | 273 | 312 | 365 | 347 |
| Sales YoY Gr. | - | 10.5% | 24.1% | 22.8% | 4.7% | 11.4% | 14.6% | -3.8% | 14.2% | 17.3% | - |
| Adj EPS ⓘ | 1.8 | 2 | 3.1 | 3.2 | 3.2 | 5.2 | 6.3 | 4.8 | 5 | 10.8 | 8.8 |
| YoY Gr. | - | 11.2% | 58.1% | 1.9% | -0.9% | 64.6% | 21.7% | -24.2% | 3.3% | 118.4% | - |
| BVPS (₹) ⓘ | 14.3 | 16 | 22.8 | 25.6 | 28.3 | 32.9 | 38.7 | 42.9 | 47 | 51.6 | 53.8 |
| Adj Net Profit ⓘ | 19.3 | 21.6 | 34.9 | 35.6 | 35.3 | 58.1 | 70.7 | 53.7 | 55.5 | 121 | 98 |
| Cash Flow from Ops. ⓘ | 33.5 | 22.3 | 21.1 | 22.6 | 35.4 | 46 | 84.2 | 37.1 | 50.3 | 55.8 | - |
| Debt/CF from Ops. ⓘ | 1.2 | 2.2 | 1.8 | 2 | 0.6 | 0.2 | 0 | 0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 12.6% | 10.5% | 8.8% | 17.3% | ||||
| Adj EPS ⓘ | 22.2% | 27.9% | 19.6% | 118.4% | ||||
| BVPSⓘ | 15.3% | 12.8% | 10.1% | 9.9% | ||||
| Share Price | - | 16.1% | 3.2% | 17.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 13.2 | 13.1 | 16.3 | 13.1 | 11.6 | 16.8 | 17.6 | 11.7 | 11 | 21.9 | 16.7 |
| Op. Profit Mgn % ⓘ | 27 | 26.8 | 28.4 | 23.3 | 23.9 | 31.5 | 35.7 | 26.7 | 24.4 | 28.8 | 25.4 |
| Net Profit Mgn % ⓘ | 15.4 | 15.5 | 20.2 | 16.8 | 15.9 | 23.5 | 25 | 19.7 | 17.8 | 33.1 | 28.4 |
| Debt to Equity ⓘ | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 236 | 224 | 199 | 205 | 234 | 223 | 203 | 230 | 220 | 194 | 136 |
| Cash Conv. Cycle ⓘ | 142 | 134 | 125 | 113 | 113 | 120 | 106 | 124 | 126 | 128 | 112 |
Return on Equity has increased versus last 3 years average to 16.70%
Net Profit is growing at healthy rate in last 3 years 19.60%
Sales growth has been subdued in last 3 years 8.84%
Sales growth is not so good in last 4 quarters at 1.78%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 8.8 | 12.3 |
| TTM Sales (₹ Cr.) | 347 | 619 |
| BVPS (₹.) ⓘ | 53.8 | 119.9 |
| Reserves (₹ Cr.) ⓘ | 580 | 1,319 |
| P/BV ⓘ | 7.02 | 3.15 |
| PE ⓘ | 42.97 | 30.86 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 313.65 / 571.15 |
| All Time Low / High (₹) | 91.05 / 571.15 |
| Market Cap (₹ Cr.) | 4,230 |
| Equity (₹ Cr.) | 22.4 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 126 | 139 | 173 | 212 | 222 | 247 | 283 | 273 | 312 | 365 |
| Operating Expenses ⓘ | 92 | 103 | 124 | 163 | 169 | 170 | 183 | 200 | 236 | 260 |
| Manufacturing Costs | 19 | 19 | 18 | 19 | 18 | 20 | 21 | 30 | 34 | 41 |
| Material Costs | 37 | 44 | 62 | 86 | 86 | 89 | 96 | 99 | 123 | 132 |
| Employee Cost | 19 | 24 | 27 | 32 | 33 | 33 | 34 | 39 | 41 | 50 |
| Other Costs ⓘ | 17 | 16 | 17 | 26 | 33 | 29 | 31 | 32 | 38 | 37 |
| Operating Profit ⓘ | 34 | 36 | 49 | 49 | 53 | 77 | 101 | 73 | 75 | 105 |
| Operating Profit Margin (%) | 26.8% | 26.1% | 28.1% | 23.3% | 23.8% | 31.1% | 35.6% | 26.7% | 24.1% | 28.8% |
| Other Income ⓘ | 1 | 1 | 6 | 6 | 6 | 9 | 7 | 9 | 10 | 59 |
| Interest ⓘ | 5 | 4 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 8 | 7 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 11 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19 |
| Profit Before Tax ⓘ | 22 | 25 | 44 | 44 | 47 | 76 | 98 | 72 | 74 | 134 |
| Tax ⓘ | 3 | 5 | 9 | 8 | 12 | 18 | 27 | 18 | 19 | 26 |
| Profit After Tax | 19 | 21 | 35 | 36 | 35 | 58 | 71 | 55 | 56 | 108 |
| PAT Margin (%) | 15.3% | 15.0% | 20.0% | 16.9% | 15.9% | 23.4% | 25.1% | 20.0% | 17.8% | 29.6% |
| Adjusted EPS (₹) | 1.8 | 1.9 | 3.1 | 3.2 | 3.2 | 5.2 | 6.4 | 4.9 | 5.0 | 9.7 |
| Dividend Payout Ratio (%) | 6% | 10% | 13% | 16% | 19% | 12% | 14% | 21% | 20% | 53% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 156 | 174 | 255 | 286 | 316 | 367 | 433 | 480 | 525 | 577 |
| Share Capital ⓘ | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves ⓘ | 134 | 152 | 233 | 264 | 294 | 345 | 410 | 457 | 503 | 555 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 28 | 45 | 33 | 40 | 18 | 9 | 0 | 0 | 0 | 0 |
| Long Term Debt | 5 | 16 | 12 | 8 | 2 | 1 | 0 | 0 | 0 | 0 |
| Short Term Debt | 22 | 29 | 21 | 32 | 17 | 8 | 0 | 0 | 0 | 0 |
| Trade Payables | 8 | 9 | 8 | 21 | 16 | 14 | 23 | 20 | 18 | 22 |
| Others Liabilities ⓘ | 31 | 32 | 21 | 25 | 26 | 33 | 34 | 30 | 32 | 34 |
| Total Liabilities ⓘ | 222 | 261 | 318 | 373 | 376 | 423 | 490 | 530 | 576 | 633 |
Fixed Assets | ||||||||||
| Gross Block | 167 | 170 | 107 | 114 | 122 | 160 | 174 | 183 | 204 | 213 |
| Accumulated Depreciation | 62 | 69 | 8 | 16 | 24 | 33 | 42 | 51 | 61 | 71 |
| Net Fixed Assetsⓘ | 106 | 101 | 98 | 98 | 97 | 127 | 132 | 132 | 143 | 142 |
| CWIP ⓘ | 4 | 7 | 8 | 10 | 7 | 10 | 7 | 9 | 11 | 22 |
| Investmentsⓘ | 27 | 53 | 103 | 120 | 120 | 121 | 184 | 189 | 201 | 256 |
| Inventories | 39 | 47 | 51 | 55 | 59 | 60 | 63 | 80 | 77 | 97 |
| Trade Receivables | 25 | 23 | 31 | 39 | 38 | 52 | 55 | 49 | 67 | 75 |
| Cash Equivalents | 1 | 2 | 1 | 0 | 1 | 3 | 2 | 18 | 25 | 19 |
| Others Assetsⓘ | 20 | 28 | 25 | 51 | 54 | 50 | 46 | 52 | 52 | 22 |
| Total Assets ⓘ | 222 | 261 | 318 | 373 | 376 | 423 | 490 | 530 | 576 | 633 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 33 | 22 | 21 | 23 | 35 | 46 | 84 | 37 | 50 | 56 |
| PBT ⓘ | 22 | 25 | 44 | 44 | 47 | 76 | 98 | 72 | 74 | 134 |
| Adjustment ⓘ | 14 | 11 | 6 | 9 | 7 | 3 | 4 | 2 | 5 | -24 |
| Changes in Working Capital ⓘ | 3 | -9 | -19 | -21 | -6 | -20 | 9 | -15 | -13 | -27 |
| Tax Paid ⓘ | -6 | -6 | -10 | -9 | -12 | -13 | -27 | -21 | -16 | -27 |
| Cash Flow From Investing Activity ⓘ | -7 | -27 | -55 | -22 | -2 | -25 | -70 | -14 | -42 | -7 |
| Capex | -4 | -1 | -7 | -7 | -4 | -41 | -9 | -9 | -23 | -21 |
| Net Investments | -1 | -26 | -50 | -16 | 0 | -1 | -63 | -9 | -22 | -40 |
| Others ⓘ | -2 | 1 | 3 | 2 | 2 | 17 | 3 | 4 | 3 | 54 |
| Cash Flow From Financing Activityⓘ | -27 | 4 | 34 | -1 | -33 | -19 | -15 | -11 | -12 | -57 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -13 | 4 | -3 | -4 | -9 | -1 | -2 | 0 | 0 | 0 |
| Interest Paid ⓘ | -4 | -4 | -3 | -3 | -2 | -1 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | -1 | -3 | 0 | -5 | -6 | -8 | -7 | -10 | -11 | -56 |
| Others ⓘ | -9 | 7 | -8 | 11 | -16 | -9 | -7 | -1 | -1 | -1 |
| Net Cash Flow ⓘ | -1 | 0 | 0 | 0 | 0 | 2 | -1 | 12 | -4 | -8 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 13.13 | 12.66 | 16.11 | 13.26 | 11.7 | 16.98 | 17.76 | 11.95 | 11.05 | 19.61 |
| ROCE (%) | 13.84 | 14.31 | 18.06 | 15.07 | 14.85 | 21.45 | 24.16 | 15.78 | 14.83 | 24.3 |
| Asset Turnover Ratio | 0.59 | 0.62 | 0.64 | 0.62 | 0.59 | 0.62 | 0.63 | 0.54 | 0.57 | 0.61 |
| PAT to CFO Conversion(x) | 1.74 | 1.05 | 0.6 | 0.64 | 1 | 0.79 | 1.18 | 0.67 | 0.89 | 0.52 | Working Capital Days |
| Receivable Days | 73 | 58 | 53 | 59 | 63 | 66 | 68 | 69 | 68 | 71 |
| Inventory Days | 104 | 107 | 98 | 90 | 93 | 87 | 78 | 96 | 92 | 87 |
| Payable Days | 82 | 69 | 51 | 63 | 78 | 60 | 69 | 79 | 57 | 55 |
The company was incorporated as a private limited company on March 15, 1989 under the provisions of the Companies Act, 1956 as Advanced Biochemicals Private Limited in Maharashtra. Pursuant to a special resolution passed by the shareholders of the Company at the extra-ordinary general meeting held on April 21, 1992, the Company was converted into a public limited company and consequently the name of the Company was changed to Advanced Biochemicals Limited. A fresh certificate of change of name reflecting the new name was issued by the Registrar of Companies, Maharashtra on May 28, 1992. Pursuant to a special resolution passed by the shareholders of their Company at the extra-ordinary general meeting held on August 8, 2005, the name of Company was further changed from Advanced Biochemicals Limited to Advanced Enzyme Technologies Limited. A fresh certificate of incorporation reflecting the new name was issued by the Registrar of Companies, Maharashtra, Mumbai on August 19, 2005.
Advanced Enzymes is a research driven company with global leadership in manufacturing of enzymes and probiotics. It is the largest Indian enzyme company engaged in the research and development, manufacturing and marketing of huge proprietary products developed from various indigenous enzymes & probiotics. The company’s aim is to help consumers’ access side-effect free healthcare, help farmers enhance nutrition for animals, and also to help the industry replace traditional thermal-chemical-mechanical processes into enzyme passed processes.
Business area of the company
The company is a fully integrated enzyme manufacturing company driven by extensive focus on research and development (R&D) of various enzymes, enzyme blends, enzyme products and customized enzyme solutions. Its experienced and qualified R&D team strives to develop creative, cost-effective unique and innovative solutions, thereby enabling their customers to develop superior products and processes. The company products assist its customers in making most of their resources, optimizing their processes, improving their product quality, saving their time and money while also mitigating the impact on the environment. It supplies these value-added and eco-safe enzyme products to diverse end-user industries like human healthcare and nutrition, animal nutrition, food processing, baking, dairy and cheese processing, fruit and vegetable processing, cereal extraction, brewing, grain processing, protein processing, oil and fat processing, biomass processing, textile processing, leather processing, paper & pulp processing, bio-fuels, bio-catalysis etc. Although, the company has the capability to manufacture enzymes using all the four natural origins viz. plant, animal, bacterial and fungal, their major focus is on developing enzymes through microbial fermentation.
Products & Solutions
Human Nutrition: The company’s enzymes are being used by a wide range of customers globally as active ingredients in their pharmaceutical and nutraceutical formulations.
Animal Nutrition: By adding its enzymes to feed, the digestibility of the feed components can be enhanced considerably.
Food Processing: The company’s enzymes play an essential role in bringing more nutrition and appeal to food & beverages products, offering significant benefits beyond the scope of traditional alternatives.
Non-Food Processing: AETL offers eco-safe solutions for a variety of industries such as textiles, leather, detergent, paper & pulp which are used in manufacturing a wide range of products.
Awards
History and Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
